1406 related articles for article (PubMed ID: 16790363)
1. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
Brabec V; Nováková O
Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
[TBL] [Abstract][Full Text] [Related]
2. Non platinum metal complexes as anti-cancer drugs.
Ott I; Gust R
Arch Pharm (Weinheim); 2007 Mar; 340(3):117-26. PubMed ID: 17315259
[TBL] [Abstract][Full Text] [Related]
3. DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media.
Novakova O; Chen H; Vrana O; Rodger A; Sadler PJ; Brabec V
Biochemistry; 2003 Oct; 42(39):11544-54. PubMed ID: 14516206
[TBL] [Abstract][Full Text] [Related]
4. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines.
Kasparkova J; Marini V; Najajreh Y; Gibson D; Brabec V
Biochemistry; 2003 May; 42(20):6321-32. PubMed ID: 12755637
[TBL] [Abstract][Full Text] [Related]
5. New platinum, titanium, and ruthenium complexes with different patterns of DNA damage in rat ovarian tumor cells.
Frühauf S; Zeller WJ
Cancer Res; 1991 Jun; 51(11):2943-8. PubMed ID: 2032232
[TBL] [Abstract][Full Text] [Related]
6. New cytotoxic and water-soluble bis(2-phenylazopyridine)ruthenium(II) complexes.
Hotze AC; Bacac M; Velders AH; Jansen BA; Kooijman H; Spek AL; Haasnoot JG; Reedijk J
J Med Chem; 2003 Apr; 46(9):1743-50. PubMed ID: 12699392
[TBL] [Abstract][Full Text] [Related]
7. Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs.
Bergamo A; Sava G
Dalton Trans; 2011 Aug; 40(31):7817-23. PubMed ID: 21629963
[TBL] [Abstract][Full Text] [Related]
8. Effects of a piperidine ligand on DNA modification by antitumor cisplatin analogues.
Kasparkova J; Novakova O; Najajreh Y; Gibson D; Perez JM; Brabec V
Chem Res Toxicol; 2003 Nov; 16(11):1424-32. PubMed ID: 14615968
[TBL] [Abstract][Full Text] [Related]
9. The effect of antitumor trans-[PtCl2(E-iminoether)2] on B-->Z transition in DNA.
Zaludová R; Natile G; Brabec V
Anticancer Drug Des; 1997 Jun; 12(4):295-309. PubMed ID: 9199661
[TBL] [Abstract][Full Text] [Related]
10. DNA binding mode of transition metal complexes, a relationship to tumor cell toxicity.
Ashfaq M; Najam T; Shah SS; Ahmad MM; Shaheen S; Tabassum R; Rivera G
Curr Med Chem; 2014; 21(26):3081-94. PubMed ID: 24934346
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
Knox RJ; Friedlos F; Lydall DA; Roberts JJ
Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
[TBL] [Abstract][Full Text] [Related]
12. Metal complexes of ruthenium: a potential class of selective anticancer drugs.
Sava G; Pacor S; Bregant F; Ceschia V
Anticancer Res; 1991; 11(3):1103-7. PubMed ID: 1888144
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines.
Pluim D; van Waardenburg RC; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2004 Jul; 54(1):71-8. PubMed ID: 15034754
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
15. DNA as a possible target for antitumor ruthenium(III) complexes.
Gallori E; Vettori C; Alessio E; Vilchez FG; Vilaplana R; Orioli P; Casini A; Messori L
Arch Biochem Biophys; 2000 Apr; 376(1):156-62. PubMed ID: 10729201
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of topoisomerase II catalytic activity by two ruthenium compounds: a ligand-dependent mode of action.
Gopal YN; Jayaraju D; Kondapi AK
Biochemistry; 1999 Apr; 38(14):4382-8. PubMed ID: 10194357
[TBL] [Abstract][Full Text] [Related]
17. Studies of the mechanism of action of platinum(II) complexes with potent cytotoxicity in human cancer cells.
Krause-Heuer AM; Grünert R; Kühne S; Buczkowska M; Wheate NJ; Le Pevelen DD; Boag LR; Fisher DM; Kasparkova J; Malina J; Bednarski PJ; Brabec V; Aldrich-Wright JR
J Med Chem; 2009 Sep; 52(17):5474-84. PubMed ID: 19658404
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic effects of gold(III) complexes on established human tumor cell lines sensitive and resistant to cisplatin.
Calamai P; Carotti S; Guerri A; Mazzei T; Messori L; Mini E; Orioli P; Speroni GP
Anticancer Drug Des; 1998 Jan; 13(1):67-80. PubMed ID: 9474243
[TBL] [Abstract][Full Text] [Related]
19. Reduction of in vivo lung metastases by dinuclear ruthenium complexes is coupled to inhibition of in vitro tumour invasion.
Bergamo A; Stocco G; Casarsa C; Cocchietto M; Alessio E; Serli B; Zorzet S; Sava G
Int J Oncol; 2004 Feb; 24(2):373-9. PubMed ID: 14719114
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium(II) based organo-metallic compounds.
Guichard SM; Else R; Reid E; Zeitlin B; Aird R; Muir M; Dodds M; Fiebig H; Sadler PJ; Jodrell DI
Biochem Pharmacol; 2006 Feb; 71(4):408-15. PubMed ID: 16360645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]